{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-23-000040","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.069078+00:00","generated_at":"2026-06-17T21:40:18.245302+00:00","sec_items":["2.02","2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Context Therapeutics discontinues ONA-XR, prioritizes CTIM-76; 2022 net loss $14.8M","bullets":["Discontinued ONA-XR due to elevated LFTs in 3 patients and competitive landscape; exploring strategic options.","Focusing on CTIM-76 (CLDN6 x CD3 bispecific) for solid tumors; IND expected Q1 2024.","Cash $35.5M at Dec 31, 2022, down from $49.7M; cash runway extended into late 2024.","2022 net loss $14.8M vs $10.5M in 2021; R&D $7.1M, G&A $7.8M.","CTIM-76 preclinical data at AACR April 17, 2023; investor R&D webinar same day."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-23-000040","json":"https://secwatch.observer/filing/0001842952-23-000040.json","markdown":"https://secwatch.observer/filing/0001842952-23-000040.md","text":"https://secwatch.observer/filing/0001842952-23-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295223000040/0001842952-23-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295223000040/cntx-20230317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:40:18.245302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b774a0bc2cd571bb05d5801628e0486f02d3a35","claim":"Context Therapeutics Inc. reported the year ended December 31, 2022 results: net income $14.8 million.","evidence_excerpt":"Context reported a net loss of $14.8 million for 2022, as compared to $10.5 million for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295223000040/0001842952-23-000040-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$14.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}